Evaxion to present new EVX-01 immune data at SITC 2026 meeting

Evaxion A/S announced on October 2, 2026 that it will present new immune data for its personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona, running November 4-8, 2026.

The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling, and will be presented both in an oral and poster presentation at the SITC meeting.¹ The data comes from the phase 2 trial testing EVX-01 alongside Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in advanced melanoma patients, where each enrolled patient received a vaccine designed and manufactured based on their individual biology.¹

The oral presentation is scheduled for Friday, November 6, 2026, with the poster session on Saturday, November 7, 2026, both presented by Mads Lausen, Senior Scientist at Evaxion.

Separately, the complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026.¹ Two-year data had shown an Objective Response Rate of 75%, with 12 of 16 patients achieving objective clinical responses including four complete responses, and 92% of patients still responding at two years with no relapses observed.¹

In the third year, patients received EVX-01 as stand-alone therapy, which the company said will provide insight into the vaccine's effect without combination anti-PD-1 therapy and potential additional durability data.¹ EVX-01 is currently being evaluated as a treatment for advanced melanoma and is described as Evaxion's lead clinical asset.¹